Cancer Research at Capital Health
Our Clinical Cancer Trials
Capital Health Cancer Center participates in many National Cancer Institute (NCI), university and pharmaceutical phase II and III clinical trials. Some studies lead to the discovery of new methods to detect and diagnose cancer, while others focus on innovative treatments before they become widely available.
Clinical trials offer patients the very latest in cancer care while giving physicians and researchers the opportunity to study the effectiveness of the treatment. Participation is entirely voluntary.
Our experienced oncologists and clinical research staff carefully review study criteria, potential benefits, risks, and other considerations with eligible patients for enrollment into a clinical study.
Once enrolled, our Clinical Research Department staff carefully monitors patients throughout the research trial and is available to answer questions.
The National Cancer Institute has a brochure “Taking Part in Cancer Treatment Research Studies” to help you understand the details of clinical trials.
Active Clinical Trials Currently Offered:
Brain Studies
OBSERVATION OR RADIATION THERAPY IN TREATING PATIENTS WITH NEWLY DIAGNOSED GRADE II MENINGIOMA THAT HAS BEEN COMPLETELY REMOVED BY SURGERY
- Study Information: NCT03180268, NCTN# NRG BN003 (https://clinicaltrials.gov/ct2/show/NCT03180268)
- Sponsor: NRG Oncology
- Collaborator: National Cancer Institute (NCI)
- Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
- Contact: Office of Clinical Research at 609-394-4130
THE USE OF THE KETOGENIC DIET AS AN ADJUVANT TO TREATMENT OF GLIOBLASTOME MULTIFORME
- Study Information: NCT N/A
- Sponsor: Capital Health
- Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
- Contact: Office of Clinical Research at 609-394-4130
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
Date added: Sep, 2024
- Study Information: NCT05685004
- Collaborator: TVAX Biomedical
- Principal Investigator: Michael Salacz, MD, Medical Director Neuro-Oncology
- Contact: Office of Clinical Research at 609-394-4133
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
- Study Information: NCT05438212
- Collaborator: NRG Oncology
- Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
- Contact: Office of Clinical Research at 609-394-4134
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Date added: Sep, 2024
- Study Information: NCT03994796
- Collaborator: Alliance for Clinical Trials in Oncology
- Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
- Contact: Office of Clinical Research at 609-394-4135
Liver and Pancreas Studies
CIRCULATING BIOMARKERS AND CANCER
- Study Information: NCT N/A
- Sponsor: Capital Health in collaboration with the Blumberg Institute, PA
- Principal Investigator: Cataldo Doria, MD, PhD, MBA, FACS, Hepato-pancreato-biliary Surgeon, Medical Director, Capital Health Cancer Center
- Contact: Office of Clinical Research at 609-394-4130
Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma
Date added: May, 2023
- Study Information: NCT04998552
- Sponsor: Capital Health System, Inc.
- Principal Investigator: Shirnett Williamson, MD, Medical Director, Radiation Oncology Services
- Contact: Office of Clinical Research at 609-394-4130
GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery
Date added: Sep, 2024
- Study Information: NCT05900037
- Collaborator: GATT Technologies BV
- Principal Investigator: Cataldo Doria, MD, PhD, MBA, FACS, HPB Surgeon & Medical Director – Cancer Center
- Contact: Office of Clinical Research at 609-394-4137
Gynecological Studies
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Date added: Sep, 2024
- Study Information:NCT04251052
- Sponsor: NRG Oncology
- Collaborator: National Cancer Institute (NCI)
- Principal Investigator: Joyce Varughese, MD, FACOG, Medical Director, Center for Gynecologic Oncology
- Contact: Office of Clinical Research at 609-394-4139
Lung Studies
SWOG S1827 (MAVERICK) TESTING WHETHER THE USE OF BRAIN SCANS ALONE INSTEAD OF BRAIN SCANS PLUS PREVENTIVE BRAIN RADIATION AFFECTS LIFESPAN IN PATIENTS WITH SMALL CELL LUNG CANCER
- Study Information: NCT04155034; NCTN # S1827 (https://clinicaltrials.gov/ct2/show/NCT04155034)
- Sponsor: Southwest Oncology Group
- Collaborator: National Cancer Institute (NCI)
- Principal Investigator: Shirnett Williamson, MD, DABR, Radiation Oncologist, Director, Radiation Oncology Services
- Contact: Office of Clinical Research at 609-394-4130
TESTING THE ADDITION OF RADIATION THERAPY TO THE USUAL IMMUNE THERAPY TREATMENT (ATEZOLIZUMAB) FOR EXTENSIVE STAGE SMALL CELL LUNG CANCER, THE RAPTOR TRIAL
- Study Information: NCT04402788; NCTN #NRG-LU007 (https://clinicaltrials.gov/ct2/show/NCT04402788)
- Sponsor: NRG Oncology
- Collaborator: National Cancer Institute (NCI)
- Principal Investigator: Khanh Nguyen, MD, MA, Radiation Oncologist
- Contact: Office of Clinical Research at 609-394-4130
Gastro-Intestinal Studies
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
Date added: Sep, 2024
- Study Information: NCT04949256
- Collaborator: Merck Sharp & Dohme LLC
- Principal investigator: Hongyan Liang, MD, PhD, Medical Oncologist
- Contact: Office of Clinical Research at 609-394-4139
Other Studies
CANCER TISSUE BIOREPOSITORY
- Study Information: NCT N/A
- Sponsor: Capital Health
- Principal Investigator: Krister Jones, MD, Pathologist, Chief, Cytopathology and Microbiology
- Contact: Office of Clinical Research at 609-394-4130
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Date added: Sep, 2024
- Study Information: NCT05334069
- Collaborator: Alliance for Clinical Trials in Oncology
- Principal Investigator: Hongyan Liang, MD, PhD, Medical Oncologist
- Contact: Office of Clinical Research at 609-394-4139
Urogenital Studies
A Study of miRNA 371 in Patients With Germ Cell Tumors
Date added: Sep, 2024
- Study Information: NCT04435756
- Collaborator: SWOG Cancer Research Network
- Principal Investigator: Charles Polotti, MD, Urologic Oncology Surgeon
- Contact: Office of Clinical Research at 609-394-4139
Breast Studies
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
Date added: May, 2023
- Study Information: NCT05568472/NCTN #S2010
- Sponsor: SWOG Cancer Research Network
- Collaborator: National Cancer Institute (NCI)
- Information provided by (Responsible Party): SWOG Cancer Research Network
- Principal Investigator: Arturo Loaiza-Bonilla, MD, MDEd, FACP, Health System Director, Office of Clinical Research
- Contact: Office of Clinical Research at 609-394-4130
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer EMBER-4
Date added: May, 2023
- Study Information: NCT05514054
- Sponsor: Eli Lilly and Company
- Information provided by (Responsible Party): Eli Lilly and Company
- Principal Investigator: Erica Linden, MD, Medical Director of Breast Oncology and Cancer Genetics
- Contact: Office of Clinical Research at 609-394-4130
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Date added: Sep, 2024
- Study Information: NCT04852887
- Sponsor: NRG Oncology
- Information provided by (Responsible Party): NRG Oncology
- Principal Investigator: Nikhil Thaker, MD, MHA, MBA, PMP, CMQ, FABS, DABR, FAMIA, Medical Director, Radiation Oncology
- Contact: Office of Clinical Research at 609-394-4133
Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial
Date added: Sep, 2024
- Study Information: NCT06216574
- Sponsor: Wake Forest University Health Sciences
- Information provided by (Responsible Party): Wake Forest University Health Sciences
- Principal Investigator: Erica A. Linden, MD, Medical Director, Breast Oncology & Cancer Genetics
- Contact: Office of Clinical Research at 609-394-4130